Last reviewed · How we verify
Huaier Granule
Huaier Granule is a Small molecule drug developed by Xi'an Jiaotong University. It is currently FDA-approved. Also known as: Z20000109#NMPA Approval Number#, Z20000109, Z20000109（NMPA Approval Number）, Niraparib.
Huaier Granule has been studied in clinical trials for various types of cancer, including breast cancer, hepatic carcinoma, and colorectal cancer. It has been used as an intervention in clinical trials alongside other treatments, such as Epirubicin and Docetaxel, for conditions like advanced breast cancer and hepatocarcinoma.
At a glance
| Generic name | Huaier Granule |
|---|---|
| Also known as | Z20000109#NMPA Approval Number#, Z20000109, Z20000109（NMPA Approval Number）, Niraparib, Jinke |
| Sponsor | Xi'an Jiaotong University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma (PHASE2)
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. (PHASE2)
- Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients (PHASE4)
- Huaier Granule and Proteinuria (PHASE2)
- Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial (PHASE3)
- Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules (PHASE4)
- A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
- Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Huaier Granule CI brief — competitive landscape report
- Huaier Granule updates RSS · CI watch RSS
- Xi'an Jiaotong University portfolio CI
Frequently asked questions about Huaier Granule
What is Huaier Granule?
Who makes Huaier Granule?
Is Huaier Granule also known as anything else?
What development phase is Huaier Granule in?
Related
- Manufacturer: Xi'an Jiaotong University — full pipeline
- Also known as: Z20000109#NMPA Approval Number#, Z20000109, Z20000109（NMPA Approval Number）, Niraparib, Jinke
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing